https://doi.org/10.55788/cdb01603
Arm D of the phase 3 SEQUOIA trial (NCT03336333) exposed 66 participants with CLL/SLL and del(17p) and/or TP53 mutations to the combination regimen of Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib plus the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax. Prof. Paolo Ghia (University Vita-Salute San Raffaele, Italy) presented the preliminary results of this study [1].
After a median follow-up of 31.6 months, the overall response rate was 100% and the complete remission (CR) plus CR with incomplete count recovery rate was 48%. Importantly, the best undetectable measurable residual disease (<10-4) rate was 59% in at least 1 peripheral blood sample (see Figure). The median progression-free survival was not reached at the time of presentation of the results, but the estimated 24-month progression-free survival rate was 94%.
Figure: Measurable residual disease rates in peripheral blood increased with longer treatment duration [1]
MRD, measurable residual disease; PB, peripheral blood.
COVID-19 (55%), diarrhoea (39%), nausea (30%), contusion (29%), and fatigue (23%) were the most frequently observed adverse events with the combination regimen. “The safety profile was overall favourable and we did not see any unexpected issues,” commented Prof. Ghia.
In conclusion, zanubrutinib plus venetoclax delivered promising preliminary efficacy results in participants with newly diagnosed CLL/SLL with del(17p) and/or TP53 mutations.
- Ma S, et al. Combination of Zanubrutinib plus venetoclax for treatment-naïve CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D. S160, EHA congress 2024, 13–16 June, Madrid, Spain.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation Next Article
High survival rates following atezolizumab consolidation in DLBCL »
« EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation Next Article
High survival rates following atezolizumab consolidation in DLBCL »
Table of Contents: EHA 2024
Featured articles
Meet the Expert: Prof. C. Ola Landgren discusses MRD as a key endpoint in haematological cancer trials
Multiple Myeloma
Isa-VRd proves its value in newly diagnosed MM in the IMROZ trial
PERSEUS: High MRD negativity rates with D-VRd and consolidation therapy and D-R maintenance in MM
Post-intensification data confirm superiority of quadruple therapy in MM
Promising phase 1 results for novel CAR T-cell therapy in MM
DREAMM 8: Belantamab mafodotin offers hope for patients with RRMM
Leukaemia
PhALLCON: Third-generation TKI superior to first-generation TKI in Ph+ ALL
APOLLO: ATRA plus ATO meets expectations in high-risk APL
Excellent phase 3 results for asciminib in chronic myeloid leukaemia
AUGMENT-101: Revumenib trial in KMT2Ar leukaemia stopped early for efficacy
FLAG-Ida plus venetoclax induces high MRD-negativity rates in AML
CD40/CD47 inhibitor shows promise in high-risk MDS and AML
ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS
Can MRD-guided azacitidine treatment improve outcomes in AML and MDS?
Can WGTS replace standard-of-care diagnostics in AML?
Non-malignant Haematology
ENERGIZE: Mitapivat meets primary efficacy endpoint in thalassaemia
Sovleplenib delivers durable responses and QoL improvements in primary ITP
Avatrombopag successful in children with chronic ITP
RUBY: Promising data for first AsCas12a gene-editing therapy in sickle cell disease
Encouraging data for ELA026 to treat secondary haemophagocytic lymphohistiocytosis
Myelofibrosis
Navitoclax plus ruxolitinib leads to spleen volume reductions in myelofibrosis
Is pelabresib plus ruxolitinib the paradigm-shifting combo therapy for myelofibrosis?
Lymphoma
The landscape of TP53 mutations and their prognostic impact in CLL
Can golcadomide plus R-CHOP become the first-line standard of care in high-risk BCL?
High survival rates following atezolizumab consolidation in DLBCL
First results for zanubrutinib plus venetoclax in del(17p)/TP53-mutated CLL/SLL
EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation
Updates from the EBMT Lymphoma Working Group: outcomes after allo- and auto-SCT for T-cell lymphoma subtypes
ECHO: Can we expect a novel standard of care in newly diagnosed MCL?
Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups
Related Articles
February 20, 2023
Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com